. Transcription of the C9orf72 hexanucleotide repeat expansion can be detected as sense and antisense RNA foci in the nucleus and cytoplasm. Despite being located in the noncoding region of the C9orf72 gene, the repeat sequence is translated through a non-canonical process called 'repeat associated non-ATG' (RAN) translation, into five different species of dipeptide protein, which also form intracellular aggregates. In addition, patients with C9orf72-related ALS/FTD usually have typical TDP-43 cytoplasmic inclusions at post-mortem. Importantly, multiple classical neuropathological studies have concluded that it is the distribution of TDP-43 pathology that correlates best with the clinical phenotype in C9orf72 patients (Davidson et al., 2016; . Various authors have thus proposed that dipeptide pathology must logically predate the development of TDP-43 pathology (Davidson et al., 2016) , and others that TDP-43 pathology is essential for development of ALS/FTD (Mackenzie and Neumann, 2016) . However, neither clinicopathological studies nor observations in mammalian models have yet allowed definitive inferences about the causal relationship between these pathological features or the temporal sequence in which they occur.
Case 2 presented by Vatsavayai et al. gives a rare insight into the temporal evolution of neuropathological features in C9orf72-positive FTD, because for the first time tissue is available from a patient with the C9orf72 hexanucleotide repeat expansion who underwent a brain resection for a separate clinical problem while in the preclinical phase of FTD. Moreover, it is from the temporal lobe, an area that commonly shows TDP-43 pathology in FTD cases. The absence of pathological TDP-43 cytoplasmic aggregation 6 years prior to clinical symptom onset, but its presence at death following the development and diagnosis of FTD confirms that dipeptide pathology and RNA foci may precede the development of TDP-43 pathology by years.
Is it therefore possible to have the clinical syndrome of FTD, and therefore presumably neurodegeneration, without TDP-43 inclusions? In another patient (Case 1) Vatsavayai et al. describe a typical history of clinically fulminant behavioural variant FTD but with relatively little evidence of neurodegeneration at autopsy, confined predominantly to the median pulvinar thalamic nucleus and the subgenual anterior cingulate cortex. This pattern of atrophy without marked frontotemporal atrophy has previously been reported by the same group in an imaging study in a subset of C9orf72-positive FTD patients (Lee et al., 2014) , with similar findings in presymptomatic subjects (Rohrer et al., 2015) . Even more striking is that the post-mortem examination of Case 1 showed only minimal TDP-43 neurites and no inclusions and did not fulfil the formal pathological criteria for the classification of FTD-TDP. Although this raises fundamental questions about the role of TDP-43 in FTD, Case 1 is currently a rare exception in the face of large case series confirming frontotemporal atrophy and TDP-43 positive inclusions as the usual features of C9orf72-related FTD.
Questions about the role of TDP-43 pathology in FTD are not new. Minimal TDP-43 pathology has previously been reported in a family with the C9orf72 hexanucleotide repeat expansion, in which the mother presented with behavioural variant FTD and had widespread dipeptide pathology but little TDP-43 pathology at post-mortem. Interestingly, her son also carried the hexanucleotide repeat expansion mutation and, on the background of a history of apparently stable learning difficulties, developed a rapidly progressive neurodegenerative condition in his 20s. He also had dipeptide pathology but no TDP-43 pathology at post-mortem. Again, relative absence of atrophy was reported in both patients though no comment was made on the pulvinar nuclei (Proudfoot et al., 2014) . Another group gave similar reports of three FTD patients with no or mild atrophy and a relative absence of TDP-43 (Baborie et al., 2015) .
The question then remains how C9orf72 positive patients with relatively little atrophy develop FTD. On a macroscopic level the work of Vatsavayai et al. revives the idea of 'thalamic dementia' in which the possibility of neuronal dysfunction in the absence of marked degeneration has been contemplated (Deymeer et al., 1989) . This is supported by their previous findings of reductions in global connectivity in C9orf72-positive FTD patients that correlated with medial pulvinar atrophy (Lee et al., 2014) . Does this mean that there are multiple pathways toward FTD in C9orf72 hexanucleotide repeat expansion carriers? And do these changes arise during ageing or is the thalamic phenotype of neurodevelopmental origin?
The absence of TDP-43 positive cytoplasmic aggregates cannot be taken as evidence that TDP-43 molecular dysfunction is not present. In Case 2, TDP-43 nuclear depletion was seen both in the presymptomatic surgical tissue and also in occasional cells without aggregates at postmortem. Whether this is an early pathological phenomenon or an artefact cannot be determined. Although Case 1 did not demonstrate TDP-43 nuclear depletion at post-mortem, the presence of a few wispy threads of TDP-43 still hints at TDP-43 dysfunction. It is possible that a combination of different molecular features (RNA foci, dipeptide repeat proteins and TDP-43 mislocalization) may contribute to C9orf72-related neurodegeneration, but in different proportions in individual patients and that the subjects in the current study are simply outliers. The longstanding debate in the field of neurodegeneration about whether inclusions are intrinsically toxic or merely a terminal marker of protein dysfunction has not been resolved. TDP-43 dysfunction rather than aggregation could provide a better unifying explanation for the cases with little frontotemporal atrophy and TDP-43 pathology.
This publication is now the fourth independent report of absent or minimal TDP-43 pathology in a patient with C9orf72-related FTD. It is noteworthy that no such cases have been reported in ALS. Moreover, studies of the geographical distribution of all subspecies of dipeptide protein have repeatedly shown that dipeptide inclusion burden and protein levels are much lower or non-existent in the spinal cord. The subtle differences between molecular pathology of C9orf72-positive ALS and FTD cases may hold an important clue to the pathophysiological mechanism of the hexanucleotide expansion itself.
